Allergan, GlaxoSmithKline to Collaborate in BOTOX Development and Sales in Japan and China.Tokyo, Japan, Oct 6, 2005 - (JCNN JCNN Japan Corporate News Network ) - Allergan announced on October 4 that it has concluded a long-term agreement with GlaxoSmithKline (GSK) to develop and market Allergan's ethical agent, BOTOX (botulinum toxin type A botulinum toxin type A
Botox, Botox Cosmetic, Dysport (UK), Vistabel (UK)
Pharmacologic class: Neurotoxin
Therapeutic class: Neuromuscular blocker
Pregnancy risk category C
Action) in Japan and China.
Under the agreement terms, GSK will receive the rights to develop and sell BOTOX from Allergan. GSK aims to expand the presence of BOTOX in the two markets while seeking new indications for the product.
BOTOX, which is currently approved in over 75 countries, is a purified protein for treating patients with serious and debilitating de·bil·i·tat·ing
Causing a loss of strength or energy.
Weakening, or reducing the strength of.
Mentioned in: Stress Reduction disorders as well as cosmetic needs. I
n Japan, the product is approved for the treatment of blepharospasm bleph·a·ro·spasm
Spasmodic winking caused by the involuntary contraction of an eyelid muscle.
spasm of the orbicularis oculi muscle of the eyelid. (uncontrollable blinking), hemifacial spasm and cervical dystonia (a movement disorder characterized by involuntary contractions of the neck muscles).
Source: JCN http://www.japancorp.net
Copyright [c] 2005 Japan Corporate News Network. All rights reserved.